$MVRBF News
Last published 3y ago
- 3y agoIGMSMVRBFMedivir's patent application for fostrox approved in ChinaPR NewswireSTOCKHOLM, June 19, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that the
- 3y agoIGMSMVRBFPia Baumann takes up her position as Chief Medical OfficerPR NewswireSTOCKHOLM, Feb. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the
- 3y agoIGMSMVRBFMedivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCCPR NewswireSTOCKHOLM, Feb. 20, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the
- 3y agoMVRBFMEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2022PR NewswireHUDDINGE, Sweden, Feb. 15, 2023 /PRNewswire/ -- Continued strong recruitment in the dose escalation part of the fostrox study. October – December Financial summary for the quarter Net turnover amounted to SEK 2.3 (13.9)
- 3y agoIGMSMVRBFMedivir to present at the Redeye Fight Cancer DayPR NewswireSTOCKHOLM, Jan. 16, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the
- 3y agoMVRBFMedivir partner Infex Therapeutics receives FDA QIDP designationPR NewswireSTOCKHOLM, Jan. 11, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its partner Infex Therapeutics, a leading anti-infectives specialist, has been granted Qualified Infectious Disease
- 3y agoIGMSMVRBFMVIRMedivir has completed a successful pre-IND meeting with the FDAPR NewswireSTOCKHOLM, Dec. 12, 2022 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today
- 3y agoIGMSMVRBFMedivir to present at the Erik Penser Bank Healthcare DayPR NewswireSTOCKHOLM, Nov. 29, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the
- 3y agoIGMSMVRBFMedivir recruits Pia Baumann as new Chief Medical OfficerPR NewswireSTOCKHOLM, Nov. 21, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Pia
- 3y agoIGMSMVRBFMedivir to present at the Redeye Life Science DayPR NewswireSTOCKHOLM, Nov. 16, 2022 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the
- 4y agoIGMSMVRBFMedivir presents new data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC Immunotherapy ConferencePR NewswireSTOCKHOLM, Nov. 9, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the
- 4y agoMVRBFMEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2022PR NewswireSTOCKHOLM, Nov. 3, 2022 /PRNewswire/ -- The measures to increase the pace of patient recruitment have yielded results. The Fostrox study is now progressing as expected. July – SeptemberFinancial summary for the
- 4y agoMVRBFMVIRNomination Committee of Medivir appointedPR NewswireSTOCKHOLM, Oct. 28, 2022 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2023. According to an
- 4y agoIGMSMVRBFMedivir to present at the H.C. Wainwright 24th Annual Global Investment ConferencePR NewswireSTOCKHOLM, Sept. 12, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will present at the H.C
- 4y agoIGMSMVRBFMedivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual MeetingPR NewswireSTOCKHOLM, Sept. 8, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that an abstract about its lead program fos
- 4y agoIGMSMVRBFMedivir to present at the Pareto Securities' Healthcare conferencePR NewswireSTOCKHOLM, Sept. 1, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Pareto Securities´ Healthcare conference on September 7, 2022. CEO Jens Lindberg will present the company and the clinical
- 4y agoIGMSMVRBFMedivir to present at the Erik Penser Bank Company DayPR NewswireSTOCKHOLM, Aug. 23, 2022 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) today announces that the company will present at the Erik Penser Bank Company Day on August 24, 2022. CEO Jens Lindberg will present the company and its plan for the ongoing cl
- 4y agoMVRBFMEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2022PR NewswireSTOCKHOLM, Aug. 19, 2022 /PRNewswire/ -- The clinical development of fostrox remains the focus April - June Financial summary for the quarter Net turnover amounted to SEK 0.5 (0.9) million. The loss before interest, tax, depreciation and amor
- 4y agoIGMSMVRBFMedivir to present at the ABGSC Life Science SummitPR NewswireHUDDINGE, Sweden, May 17, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ABGSC Life Science Summit on May 18, 2022. The company will be represented by CEO Jens Lindberg. The presentation
- 4y agoIGMSMVRBFResolutions at the Annual General Meeting in Medivir on 5 May 2022PR NewswireHUDDINGE, Sweden, May 5, 2022 /PRNewswire/ -- Medivir Aktiebolag (publ) held its annual shareholders' meeting today on 5 May 2022. The annual general meeting was held by physical presence of shareholders and with the option for shareholders to exercise t
- 4y agoMVRBFMEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2022PR NewswireHUDDINGE, Sweden, April 28, 2022 /PRNewswire/ -- Momentum in several areas, not least the development of our cutting-edge project fostroxacitabine bralpamide January – MarchFinancial summary for the quarter Net turnover amounted to SEK 0.5 (9.9)
- 4y agoIGMSMVRBFMedivir to present at the Redeye Orphan Drugs ConferencePR NewswireSTOCKHOLM, April 25, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Orphan Drugs Conference on April 27, 2022. CEO Jens Lindberg will present at 15.15 CET. The presentation is live
- 4y agoIGMSMVRBFMedivir to participate at the Kempen Life Sciences ConferencePR NewswireSTOCKHOLM, Sweden, April 19, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will participate at the Kempen Life Sciences Conference, April 21. More information about the event is available at the organizer's
- 4y agoIGMSMVRBFMedivir 2021 Annual Report publishedPR NewswireSTOCKHOLM, April 5, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2021 now is available at the company's website: www.medivir.com. 2021 started off with the licensing of birinapant to IGM Bioscienc
- 4y agoMVRBFNotice of Annual General Meeting of Medivir AB (publ)PR NewswireHUDDINGE, Sweden, April 4, 2022 /PRNewswire/ -- The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the Annual General Meeting on Thursday 5 May 2022 at 14.00 CEST at IVA
- 4y agoIGMSMVRBFMVIRA subgroup analysis of Medivir's phase II study of MIV-711 for osteoarthritis shows statistically significant reduction in OA painPR NewswireSTOCKHOLM, Feb. 28, 2022 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR) today announces that an article entitled "Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis o
- 4y agoIGMSMVRBFMedivir to present at the Erik Penser Bank Health Care DayPR NewswireSTOCKHOLM, Feb. 22, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that its new CEO Jens Lindberg will participate at the Erik Penser Bank Health Care Day, Thursday February 24, 2022. Jens Lindberg took office at Medivir on Ja
- 4y agoMVRBFMEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2021PR NewswireHUDDINGE, Sweden, Feb. 15, 2022 /PRNewswire/ -- October – December Financial summary for the quarter Net turnover amounted to SEK 13.9 (1.5) million. The loss before interest, tax, depreciation and amortization (EBITDA) a
- 4y agoIGMSMVRBFMedivir's MIV-818 obtains the International Nonproprietary Name fostroxacitabine bralpamidePR NewswireSTOCKHOLM, Jan. 18, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR-B) today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) fostroxacitabine bralpamide as the official generic name for
- 4y agoIGMSMVRBFJens Lindberg takes office as CEO of Medivir on January 24PR NewswireSTOCKHOLM, Jan. 17, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that Jens Lindberg will assume his position as CEO on January 24, 2022. Magnus Christensen, who has been interim CFO since the Annual General Meeting on May 5,
- 4y agoIGMSMVRBFMedivir to present at the H.C. Wainwright BioConnect Virtual ConferencePR NewswireSTOCKHOLM, Jan. 10, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright BioConnect Virtual Conference, January 10-13. The presentation will be available via Medi
- 4y agoIGMSMVRBFFirst patient dosed in the MIV-818 combination studyPR NewswireSTOCKHOLM, Dec. 14, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with hepatocellular carcinoma (HCC) has been dosed with MIV-818 in a phase 1b/2a combination study with the company's candidate drug MIV
- 4y agoIGMSMVRBFMedivir to present at the Erik Penser Bank Life Science DayPR NewswireSTOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Erik Penser Bank Life Science Day, Thursday December 2, 2021. The presentation will be available after the meeting on Medi
- 4y agoIGMSMVRBFResults from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma publishedPR NewswireSTOCKHOLM, Nov. 18, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC) has been published in JAMA Dermatology by Ki
- 5y agoIGMSMVRBFMedivir to present at the Redeye Life Science DayPR NewswireSTOCKHOLM, Nov. 11, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Life Science Day, at 1pm CET today, November 11, 2021. The presentation is live broadcasted and can be followed at
- 5y agoIGMSMVRBFBirinapant clinical study initiated by IGM BiosciencesPR NewswireSTOCKHOLM, Nov. 4, 2021 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid cancers with birinapant (a k a IGM-9427) in combination with IGM's DR5 agonist antibody IGM-8
- 5y agoMVRBFMedivir AB - Interim Report January - September 2021PR NewswireHUDDINGE, Sweden, Nov. 3, 2021 /PRNewswire/ -- Positive MIV-818 data presented at ESMO. New positive data and renegotiated agreement for remetinostat July – SeptemberFinancial summary for the quarter Net turnover amounted t
- 5y agoIGMSMVRBFNomination Committee of Medivir appointedPR NewswireSTOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2022. According to an AGM resolution, the Nomination Committee
- 5y agoIGMSMVRBFMedivir Appoints Jens Lindberg as Chief Executive OfficerPR NewswireSTOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharmaceutical industry and the
- 5y agoIGMSMVRBFA joint patent application for MALT1 inhibitors publishedPR NewswireSTOCKHOLM, Oct. 15, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that a joint patent application for MALT1 inhibitors submitted together with Rheos Medicines, Inc., a US-based biopharmaceutical company, has been made public.
- 5y agoIGMSMVRBFMedivir to present at the ProHearings shared Capital Markets DayPR NewswireSTOCKHOLM, Oct. 11, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets Day, October 14, 2021. The presentation will be available through Medivir´s website;
- 5y agoIGMSMVRBFMVIRMedivir invites to a conference call on new clinical data and further studies with MIV-818PR NewswireSTOCKHOLM, Sept. 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed dose escalation section of the phase 1b study with MIV-818, presented today at the European Soc
- 5y agoIGMSMVRBFMVIRAbstract for MIV-818 phase 1b monotherapy for ESMO Congress publishedPR NewswireSTOCKHOLM, Sept. 13, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled "Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA)
- 5y agoIGMSMVRBFMVIRMedivir to present at the Wainwright Annual Global Investment ConferencePR NewswireSTOCKHOLM, Sept. 10, 2021 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright Annual Global Investment Conference, September 13-15. The presentation will be available
- 5y agoIGMSMVRBFMVIRMedivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818PR NewswireSTOCKHOLM, Aug. 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the company has received regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for its upcoming phase 1/2a combinat
- 5y agoMVRBFMedivir AB - Interim Report January - June 2021PR NewswireHUDDINGE, Sweden, Aug. 19, 2021 /PRNewswire/ -- April – JuneFinancial summary for the quarter Net turnover amounted to SEK 0.9 (4.0) million. The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -17.1 (-12.4) mi
- 5y agoIGMSMVRBFMVIRMedivir strengthens the business development potential of remetinostat through renegotiated multi-party agreementPR NewswireHUDDINGE, Sweden, Aug. 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Company") together with the originators of remetinostat, and TetraLogic Pharmaceuticals Corporation and The Leukemia &
- 5y agoIGMSMVRBFMVIRPositive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer ResearchPR NewswireSTOCKHOLM, Aug. 12, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients has been published in Cli
- 5y agoIGMSMVRBFMVIRData from Medivir's MIV-818 phase 1b study to be presented at the ESMO CongressPR NewswireHUDDINGE, Aug. 5, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled "Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarc
- 5y agoIGMSMVRBFMVIRMedivir appoints Malene Jensen as VP Clinical DevelopmentPR NewswireSTOCKHOLM, July 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She will assume her role as VP Clinical Development after the summer, at the latest Octob